In an in-depth interview with The Cancer Letter, an FDA official clarified the agency’s criteria for approval of drugs that target PD-1 and PD-L1.
How is the enterprise of cancer research doing after the first 100 days of the Trump administration?
FDA Eager to Approve PD-1 and PD-L1 Drugs in Novel Combinations, New Settings
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
The cancer center program of the NCI is a success that is admired not only within the NIH but worldwide. This is due, in large part, to the cancer center review process that has evolved and strengthened over the years.
Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, was named director of the FDA Center for Biologics Evaluation and Research, where he will be responsible for the agency’s regulation of vaccines and biologics, including cell and gene therapies.
As the number of cancer survivors in the U.S. continues to rise and the age at diagnosis for some cancers appears to be shifting younger, the need for long-term survivorship care is more urgent than ever.
I joined Translational Genomics Research Institute, part of City of Hope, late last year to launch the Center for Accelerated Nanotherapeutics.
As the Trump administration reshapes the cancer research enterprise that was built on the foundation of the National Cancer Act of 1971, the Cancer History Project presents an eyewitness account of the impact of this landmark law.
